Zheng Hao, Li Man, Chi Bing, Wu Xiao-xue, Wang Jia, Liu Dian-Wu
Department of Ultrasonography, Hebei Chest Hospital, Shijiazhuang, 050041 Hebei Province, China.
Department of Epidemiology and Biostatistics, School of Public Health, Hebei Medical University, Zhongshan East Road 361#, Shijiazhuang, 050017 Hebei Province, China.
Clin Res Hepatol Gastroenterol. 2015 Oct;39(5):576-83. doi: 10.1016/j.clinre.2015.01.009. Epub 2015 Mar 10.
The IL-28B rs12979860 CC and rs8099917 TT genotypes were proved to be predictor for pegylated-interferon (PEG-IFN)/ribavirin (RBV)-treated hepatitis C virus (HCV) patients. However, there were no identical conclusions on rs12980275 polymorphism. Our aim is to perform a meta-analysis in order to determine the association between rs12980275 polymorphism of IL28B and the sustain viral response (SVR) of HCV patients with PEG-IFN/RBV therapy.
Studies were retrieved from PubMed and Chinese China National Knowledge Infrastructure (CNKI). Data were extracted by two investigators and analyzed using Stata 11.0 software.
Sixteen articles, containing 19 independent studies were included in the analysis. The results showed that patients with AA genotype of rs12980275 achieved higher SVR than patients with AG/GG genotypes. The overall OR (95% CI) was 3.118 (2.146, 4.529). In subgroup analysis by ethnicity, the ORs (95% CIs) were 3.084 (1.454, 6.542) and 2.736 (1.863, 4.018) in Asian and Caucasian population, respectively. Another subgroup analysis by HCV genotype, the ORs (95% CIs) were 3.976 (2.568, 6.158), 1.462 (0.504, 4.240) and 1.489 (0.916, 2.421) in patients with HCV genotype 1/4, mix genotype, and HCV genotype 2/3, respectively.
AA genotype of rs12980275 was a predictive factor for SVR in HCV patients with PEG-IFN/RBV treatment, especially in HCV genotype 1/4.
IL-28B rs12979860 CC和rs8099917 TT基因型已被证明是聚乙二醇干扰素（PEG-IFN）/利巴韦林（RBV）治疗丙型肝炎病毒（HCV）患者的预测指标。然而，关于rs12980275多态性尚无一致结论。我们的目的是进行一项荟萃分析，以确定IL28B rs12980275多态性与接受PEG-IFN/RBV治疗的HCV患者持续病毒学应答（SVR）之间的关联。
从PubMed和中国知网（CNKI）检索研究。由两名研究人员提取数据，并使用Stata 11.0软件进行分析。
分析纳入了16篇文章，包含19项独立研究。结果显示，rs12980275 AA基因型患者的SVR高于AG/GG基因型患者。总体比值比（95%可信区间）为3.118（2.146，4.529）。按种族进行亚组分析时，亚洲和白种人群的比值比（95%可信区间）分别为3.084（1.454，6.542）和2.736（1.863，4.018）。按HCV基因型进行另一亚组分析时，HCV 1/4型、混合基因型和HCV 2/3型患者的比值比（95%可信区间）分别为3.976（2.568，6.158）、1.462（0.504，4.240）和1.489（0.916，2.421）。
rs12980275 AA基因型是接受PEG-IFN/RBV治疗的HCV患者SVR的预测因素，尤其是在HCV 1/4型患者中。
